Literature DB >> 9119023

Expression and characterisation of plasmepsin I from Plasmodium falciparum.

R P Moon1, L Tyas, U Certa, K Rupp, D Bur, C Jacquet, H Matile, H Loetscher, F Grueninger-Leitch, J Kay, B M Dunn, C Berry, R G Ridley.   

Abstract

Two aspartic proteinases, plasmepsins I and II, are present in the digestive vacuole of the human malarial parasite Plasmodium falciparum and are believed to be essential for parasite degradation of haemoglobin. Here we report the expression and kinetic characterisation of functional recombinant plasmepsin I. In order to generate active plasmepsin I from its precursor, an autocatalytic cleavage site was introduced into the propart of the zymogen by mutation of Lys110P to Val (P indicates a propart residue). Appropriate refolding of the mutated zymogen then permitted pH-dependent autocatalytic processing of the zymogen to the active mature proteinase. A purification scheme was devised that removed aggregated and misfolded protein to yield pure, fully processable, proplasmepsin I. Kinetic constants for two synthetic peptide substrates and four inhibitors were determined for both recombinant plasmepsin I and recombinant plasmepsin II. Plasmepsin I had 5-10-fold lower k(cat)/Km values than plasmepsin II for the peptide substrates, while the aspartic proteinase inhibitors, selected for their ability to inhibit P. falciparum growth, were found to have up to 80-fold lower inhibition constants for plasmepsin I compared to plasmepsin II. The most active plasmepsin I inhibitors were antagonistic to the antimalarial action of chloroquine on cultured parasites. Northern blot analysis of RNA, isolated from specific stages of the erythrocytic cycle of P. falciparum, showed that the proplasmepsin I gene is expressed in the ring stages whereas the proplasmepsin II gene is not transcribed until the later trophozoite stage of parasite growth. The differences in kinetic properties and temporal expression of the two plasmepsins suggest they are not functionally redundant but play distinct roles in the parasite.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9119023     DOI: 10.1111/j.1432-1033.1997.00552.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  24 in total

Review 1.  Structural aspects of activation pathways of aspartic protease zymogens and viral 3C protease precursors.

Authors:  A R Khan; N Khazanovich-Bernstein; E M Bergmann; M N James
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-28       Impact factor: 11.205

2.  Antimalarial synergy of cysteine and aspartic protease inhibitors.

Authors:  A Semenov; J E Olson; P J Rosenthal
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

Review 3.  Malaria parasite plasmepsins: More than just plain old degradative pepsins.

Authors:  Armiyaw S Nasamu; Alexander J Polino; Eva S Istvan; Daniel E Goldberg
Journal:  J Biol Chem       Date:  2020-05-04       Impact factor: 5.157

4.  Structural insights into the activation and inhibition of histo-aspartic protease from Plasmodium falciparum.

Authors:  Prasenjit Bhaumik; Huogen Xiao; Koushi Hidaka; Alla Gustchina; Yoshiaki Kiso; Rickey Y Yada; Alexander Wlodawer
Journal:  Biochemistry       Date:  2011-09-26       Impact factor: 3.162

5.  Molecular and biochemical characterization of hemoglobinase, a cysteine proteinase, in Paragonimus westermani.

Authors:  Joon-Hyuck Choi; Jae-Hyuk Lee; Hak-Sun Yu; Hae-Jin Jeong; Jin Kim; Yeon-Chul Hong; Hyun-Hee Kong; Dong-Il Chung
Journal:  Korean J Parasitol       Date:  2006-09       Impact factor: 1.341

6.  Antimalarial activity enhancement in hydroxymethylcarbonyl (HMC) isostere-based dipeptidomimetics targeting malarial aspartic protease plasmepsin.

Authors:  Koushi Hidaka; Tooru Kimura; Adam J Ruben; Tsuyoshi Uemura; Mami Kamiya; Aiko Kiso; Tetsuya Okamoto; Yumi Tsuchiya; Yoshio Hayashi; Ernesto Freire; Yoshiaki Kiso
Journal:  Bioorg Med Chem       Date:  2008-10-10       Impact factor: 3.641

7.  Evidence for a central role for PfCRT in conferring Plasmodium falciparum resistance to diverse antimalarial agents.

Authors:  David J Johnson; David A Fidock; Mathirut Mungthin; Viswanathan Lakshmanan; Amar Bir Singh Sidhu; Patrick G Bray; Stephen A Ward
Journal:  Mol Cell       Date:  2004-09-24       Impact factor: 17.970

8.  Recombinant plasmepsin 1 from the human malaria parasite plasmodium falciparum: enzymatic characterization, active site inhibitor design, and structural analysis.

Authors:  Peng Liu; Melissa R Marzahn; Arthur H Robbins; Hugo Gutiérrez-de-Terán; David Rodríguez; Scott H McClung; Stanley M Stevens; Charles A Yowell; John B Dame; Robert McKenna; Ben M Dunn
Journal:  Biochemistry       Date:  2009-05-19       Impact factor: 3.162

9.  Heme binding contributes to antimalarial activity of bis-quaternary ammoniums.

Authors:  Giancarlo A Biagini; Eric Richier; Patrick G Bray; Michèle Calas; Henri Vial; Stephen A Ward
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

10.  Role of Plasmodium falciparum digestive vacuole plasmepsins in the specificity and antimalarial mode of action of cysteine and aspartic protease inhibitors.

Authors:  Pedro A Moura; John B Dame; David A Fidock
Journal:  Antimicrob Agents Chemother       Date:  2009-09-14       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.